GlaxoSmithKline News and Research

RSS

CDC and AAFP recommend whooping cough vaccine for adults and adolescents

Many people may think of whooping cough as a disease of the past -- something eradicated generations ago. However, the number of cases reported by the Centers for Disease Control and Prevention (CDC) indicate that whooping cough (pertussis) is still very much a public health concern; health experts estimate that up to 600,000 cases occur each year in adults alone. In fact, whooping cough cases are on the rise in San Diego

6 Jan 2010

Coformulation of rilpivirine and Truvada HIV drugs will achieve sales of more than $2 billion in 2018

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in 2018, the fixed dose coformulation of Tibotec's rilpivirine and Gilead's Truvada will achieve blockbuster sales of more than $2 billion in the HIV drug market in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

5 Jan 2010

FDA accepts NDA review for new anticonvulsant drug

The U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) seeking marketing approval for Retigabine. In addition, the European Medicines Agency (EMEA) confirmed on November 17, 2009 that the MAA (Marketing Authorization Application) was successfully validated thus enabling the MAA review to commence.

30 Dec 2009

Achievements in lupus research, education and advocacy cause for celebration and hope

The year 2009 will be remembered as a year of many firsts for lupus, including the first successful phase III clinical trial of a potential new treatment for lupus, the launch of the first-ever Ad Council public awareness campaign for lupus, and the first comprehensive report on the barriers to lupus drug development. And it appears there are no signs of any slowing of momentum as we enter the New Year.

23 Dec 2009

CEO Cancer Gold Standard accreditation for Aldagen

Aldagen, Inc. has received CEO Cancer Gold Standard™ accreditation, recognizing the company’s commitment to taking concrete actions to reduce the cancer risk of its employees and their families through screenings, early detection, and healthy changes in lifestyle and in the workplace.

23 Dec 2009

LadaTech files patent infringement lawsuit against Illumina

LadaTech announced today that it has served its complaint upon Illumina, Inc. in its lawsuit for patent infringement in the United States District Court for the District of Delaware. LadaTech is jointly owned by GlaxoSmithKline and IP Finance Holdings.

From Illumina, Inc. 22 Dec 2009

Prasco Laboratories to market Stiefel Laboratories' Clobetasol Propionate Foam

Prasco Laboratories announced today that they have signed a distribution and supply agreement with Stiefel Laboratories, Inc., a GlaxoSmithKline company, for Clobetasol Propionate Foam 0.05%, the latest product in Prasco's line of authorized generics. Under the terms of the agreement, Prasco will market and distribute Clobetasol Propionate Foam 0.05% in 50g and 100g canisters in the U.S. under the Prasco label.

22 Dec 2009

Seattle Genetics and GSK sign ADC collaboration agreement

Seattle Genetics, Inc., announced today that it has entered into a collaboration agreement with GlaxoSmithKline (GSK) under which GSK will pay an upfront fee of $12 million for rights to utilize Seattle Genetics’ antibody-drug conjugate (ADC) technology with multiple antigens to be named by GSK.

21 Dec 2009

GSK receives European CHMP positive opinion for Revolade

Ligand Pharmaceuticals Incorporated today announced that its partner GlaxoSmithKline has received a positive opinion for Revolade® (eltrombopag/Promacta®) from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for the oral treatment of thrombocytopenia (reduced platelet count) in adults with the blood disorder chronic immune (idiopathic) thrombocytopenic purpura (ITP).

18 Dec 2009

GSK and NanoBio sign license agreement for nanoemulsion technology

GlaxoSmithKline and Ann Arbor-based NanoBio Corporation announced today that they have signed an exclusive over-the-counter licensing agreement for NanoBio's unique nanoemulsion treatment for cold sores in the United States and Canada.

17 Dec 2009

WHO using new bivalent oral polio vaccine in Afghanistan

The WHO on Tuesday launched a vaccination campaign in Afghanistan that will use "a new and more effective polio vaccine" for the first time, Reuters reports (Nebehay, 12/15).

16 Dec 2009

More details emerge about UNITAID's plan for patent pool for HIV/AIDS drugs

News outlets continued to follow UNITAID's recent announcement to create a patent pool aimed at lowering the cost of HIV/AIDS drugs for low- and middle-income countries. Though UNITAID's board "voted Monday to create a board to run the new patent pool, and set a target of having five AIDS drugs in the pool by mid-2010," the group "punted on the thorny issue of which countries outside of Africa to include in the pool," Forbes reports.

16 Dec 2009

NanoBio, GSK partner to develop and commercialize novel cold sore treatment compound

GlaxoSmithKline plc and NanoBio Corporation today announced an exclusive licensing agreement in the United States and Canada for the over-the-counter (OTC) use of NB-001, a novel, patented compound representing the next advance in the treatment of cold sores. Developed by NanoBio, NB-001 provides significant antimicrobial activity against the virus that causes cold sores, herpes labialis.

16 Dec 2009

Combination therapy improves overall survival in women with advanced breast cancer

In a clinical study, women with an aggressive form of breast cancer experienced a median survival of 14 months when treated with an investigational combination of TYKERB® (lapatinib) plus HERCEPTIN® (trastuzumab). The results of the Phase III study in HER2-positive metastatic breast cancer were presented during the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held in San Antonio, Texas (Dec. 9 - 13).

14 Dec 2009

Avandia lawsuit: GSK's claims of privilege rejected

In a decision of importance to the case at hand and all cases involving claims of attorney-client or work product privilege, the Honorable Cynthia M. Rufe of the United States District Court for the Eastern District of Pennsylvania, in a decision of December 7, 2009, has ruled that GlaxoSmithKline (GSK), the manufacturer of the prescription diabetes medication Avandia, must produce dozens of documents that it withheld on claims of privilege.

11 Dec 2009

Flu vaccine shortages in developing countries could destabilize global security, says former WHO deputy head

"Flu vaccine shortages in developing nations may destabilize global security should the H1N1 [swine flu] virus become more deadly … David Heymann, a former deputy head of the World Health Organization" said Monday, Bloomberg reports.

10 Dec 2009

Despite worldwide outbreak of H1N1 virus, American adults not eager to get vaccinated

American adults are not being vaccinated against the seasonal flu any more often than they were last year, despite increased public discussion of the importance of influenza vaccines resulting from the worldwide outbreak of the H1N1 virus, according to a new RAND Corporation study.

10 Dec 2009

Study reveals increased discussion on flu vaccines has no significant impact on public's behavior

Seasonal flu vaccination rates among American adults have only slightly improved over last year, despite increased public discussion of the importance of influenza vaccines resulting from the worldwide outbreak of the H1N1 virus.

10 Dec 2009

Second pivotal Phase 3 trial to evaluate investigational Lp-PLA2 inhibitor darapladib initiated

Attached is a press release issued earlier this morning by GlaxoSmithKline, announcing that GSK has initiated its second pivotal Phase 3 trial to evaluate the efficacy of long-term treatment with the investigational Lp-PLA2 inhibitor darapladib in men and women with acute coronary syndrome (ACS).

10 Dec 2009

Pharma IQ to organize Anti-Infectives Summit in Philadelphia

Organized by Pharma IQ, a division of IQPC, the Anti-Infectives Summit will be held January 25-27, 2010 in Philadelphia, PA (www.anti-infectivesummit.com). This forum explores recent advances within anti-infective drug discovery and development, and is geared towards Chief Scientific Officers and Scientists working in microbiology, immunology, infectious diseases, medicinal chemistry and drug development.

From IQPC Ltd 10 Dec 2009

GlaxoSmithKline News and Research

CDC and AAFP recommend whooping cough vaccine for adults and adolescents

Coformulation of rilpivirine and Truvada HIV drugs will achieve sales of more than $2 billion in 2018

FDA accepts NDA review for new anticonvulsant drug

Achievements in lupus research, education and advocacy cause for celebration and hope

CEO Cancer Gold Standard accreditation for Aldagen

LadaTech files patent infringement lawsuit against Illumina

Prasco Laboratories to market Stiefel Laboratories' Clobetasol Propionate Foam

Seattle Genetics and GSK sign ADC collaboration agreement

GSK receives European CHMP positive opinion for Revolade

GSK and NanoBio sign license agreement for nanoemulsion technology

WHO using new bivalent oral polio vaccine in Afghanistan

More details emerge about UNITAID's plan for patent pool for HIV/AIDS drugs

NanoBio, GSK partner to develop and commercialize novel cold sore treatment compound

Combination therapy improves overall survival in women with advanced breast cancer

Avandia lawsuit: GSK's claims of privilege rejected

Flu vaccine shortages in developing countries could destabilize global security, says former WHO deputy head

Despite worldwide outbreak of H1N1 virus, American adults not eager to get vaccinated

Study reveals increased discussion on flu vaccines has no significant impact on public's behavior

Second pivotal Phase 3 trial to evaluate investigational Lp-PLA2 inhibitor darapladib initiated

Pharma IQ to organize Anti-Infectives Summit in Philadelphia

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News